- Home
- ILAG vs BIAF Comparison
ILAG vs BIAF Comparison
Compare ILAG & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ILAG | BIAF |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | 57 |
| Industry | Office Equipment/Supplies/Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 4.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ILAG | BIAF |
|---|---|---|
| Price | $2.10 | $4.59 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.4K | ★ 18.8M |
| Earning Date | 04-27-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.16 |
| 52 Week High | $7.19 | $13.50 |
Technical Indicators
Market Signals| Indicator | ILAG | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 42.28 | 76.19 |
| Support Level | $2.04 | $0.76 |
| Resistance Level | $3.31 | $7.29 |
| Average True Range (ATR) | 0.21 | 0.75 |
| MACD | 0.00 | 0.31 |
| Stochastic Oscillator | 11.10 | 85.60 |
Price Performance
Historical ComparisonAbout ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.